SCHEMBL193400

SCHEMBL193400

CCCN1CC(=O)NC1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 3/20 0.50
L3MBTL1 Q9Y468 1/20 0.38
TOP2A P11388 2/20 0.37
TOP2B Q02880 2/20 0.37
ALDH1A1 P00352 2/20 0.37
MAPT P10636 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
LMNA P02545 3/20 0.34
PTGS1 P23219 2/20 0.34
CYP4F2 P78329 1/20 0.34
CYP4A11 Q02928 1/20 0.34
DDB1 Q16531 2/20 0.33
EPHX2 P34913 1/20 0.33
KDM4E B2RXH2 1/20 0.32
CYP2C19 P33261 1/20 0.32
GAA P10253 2/20 0.32
TSHR P16473 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
PARP1 P09874 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL194067 0.87 CRBN (0.46) CRBNL3MBTL1TOP2ATOP2BALDH1A1
SCHEMBL461664 0.85 CRBN (0.45) CRBNALDH1A1MAPTLMNAPTGS1
SCHEMBL8716131 0.84 ALOX5 (0.45) CRBNALDH1A1LMNAPTGS1CYP4F2
SCHEMBL162839 0.84 ALOX5 (0.45) CRBNALDH1A1LMNAPTGS1CYP4F2
SCHEMBL20376257 0.84 ALOX5 (0.45) CRBNALDH1A1LMNAPTGS1CYP4F2
SCHEMBL6233217 0.84 ALOX5 (0.45) CRBNALDH1A1LMNAPTGS1CYP4F2
SCHEMBL6228568 0.84 ALOX5 (0.45) CRBNALDH1A1LMNAPTGS1CYP4F2
SCHEMBL6233785 0.84 ALOX5 (0.45) CRBNALDH1A1LMNAPTGS1CYP4F2
SCHEMBL20441211 0.84 ALOX5 (0.45) CRBNALDH1A1LMNAPTGS1CYP4F2
SCHEMBL3628533 0.84 ALOX5 (0.45) CRBNALDH1A1LMNAPTGS1CYP4F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108430442-A It include the method for handling keratin fiber using the composition comprising urea or derivatives thereof, polyalcohol and amodimethicone 欧莱雅 2018-08-21 CN claimed
EP-3601291-B1 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN SITEONE THERAPEUTICS INC (US) 2026-05-20 EP disclosed
US-12162886-B2 11,13-modified saxitoxins for the treatment of pain SITEONE THERAPEUTICS, INC. (US) 2024-12-10 US disclosed
EP-3639821-B1 CARCINOGENESIS INHIBITOR NAT CANCER CT (JP) 2024-08-28 EP disclosed
US-11834456-B2 11,13-modified saxitoxins for the treatment of pain SITEONE THERAPEUTICS, INC. (US) 2023-12-05 US disclosed
US-11834456-B2 11,13-modified saxitoxins for the treatment of pain SITEONE THERAPEUTICS, INC. (US) 2023-12-05 US disclosed
EP-3860714-B1 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN SITEONE THERAPEUTICS INC (US) 2023-09-06 EP disclosed
US-20230259028-A1 RESIST UNDERLAYER FILM-FORMING COMPOSITION CONTAINING REACTION PRODUCT OF HYDANTOIN COMPOUNDS NISSAN CHEMICAL CORPORATION (JP) 2023-08-17 US disclosed
CN-110831945-B 11, 13-modified saxitoxins for the treatment of pain 赛特温治疗公司 2023-08-08 CN disclosed
CN-116194211-A Method and apparatus for producing ammonia 日产化学株式会社 2023-05-30 CN disclosed
US-5827717-A GENE CODING FOR A CARBAMOYLASE, HYDANTOINASE OR HYDANTOIN RACEMASE DEGUSSA AKTIENGESELLSCHAFT (DE) 1998-10-27 US disclosed
WO-1997043264-A1 COMPOSITIONS AND METHODS UTILIZING 1,3-BROMOCHLORO-5-METHYL-5-PROPYLHYDANTOIN GREAT LAKES CHEMICAL CORPORATION (US) 1997-11-20 WO disclosed
EP-0780125-A2 Pharmaceutical composition containing a hydantoin derivative and use of said derivative NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 1997-06-25 EP disclosed
US-5516660-A FROM CORRESPONDING HYDANTOINS OR CARBAMOYL AMINO ACIDS;ENZYMATIC CONVERSION IN PRESENCE OF ARTHOBACTER DEGUSSA AKTIENGESELLSCHAFT (DE) 1996-05-14 US disclosed
EP-0571904-B1 Process for preparing methylolhydantoins LONZA AG (US) 1995-10-25 EP disclosed
EP-0571904-A1 Process for preparing methylolhydantoins LONZA INC. (US) 1993-12-01 EP disclosed
US-5252744-A Liquid based methods for the production of solid, anhydrous methylolhydantoins LONZA INC. (US) 1993-10-12 US disclosed
EP-0358188-A2 Electrically conductive composition with polyheteroaromates and polymer sulfates Japat Ltd (CH) 1990-03-14 EP disclosed
US-4537697-A Method of enhancing solubility of halogenated hydantoins GLYCO, INC. (US) 1985-08-27 US disclosed
EP-0031996-A1 Hydantoinylsilanes and bis(hydantoinyl)disiloxanes and method for preparing same M & T CHEMICALS, INC. (US) 1981-07-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11834456-B2 11,13-modified saxitoxins for the treatment of pain SCN11A, SCN10A, CACNA1A CRBN 3204/4885L3MBTL1 3602/4885TOP2A 3569/4885
US-12162886-B2 11,13-modified saxitoxins for the treatment of pain SCN11A, SCN10A, SCN3A CRBN 4496/4885L3MBTL1 4079/4885TOP2A 3602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.